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PEPTIDE-DRUG CONJUGATE FOR HER2-TARGETED DRUG DELIVERY

Abstract

By Yan Wang
University of the Pacific
2018
Recent strategies for anticancer drug design have been focused on utilizing
antibody as a drug or targeted moiety for targeted drug delivery. Antibody−drug
conjugates (ADCs) have become a promising new class of targeted therapeutic agents
for treatment of cancer. ADCs are designed to preferentially direct a cytotoxic drug to
a cell-surface antigen recognized by an antibody. However, there are some challenges
in developing ADCs, such as limited solid tumor penetration, high manufacturing
costs and antibody-drug stoichiometry. Smaller molecules such as peptides have been
shown to specifically bind to cancer related targets. These peptides can be used to
form peptide-drug conjugates (PDCs) to overcome above-mentioned drawbacks
presented by ADCs.
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In this study, it was hypothesized that novel synthesized PDCs can be a strategy
for breast cancer therapy. HER2 specific binding peptides, MARAKE and MARSGL,
were modified by addition of a cysteine at C-terminus. The modified peptides were
coupled with monomethylauristatin E (MMAE) by using maleimidocaproyl (MC) as a
non-cleavable linker to form peptide-drug conjugates (YW1, YW2) and
maleimidocaproyl-valine-citrulline (MC-VC) as a cleavable linker to form
peptide-drug conjugates (YW3 and YW4). The peptides, peptide-drug conjugates and
MC-MMAE, MC-VC-MMAE were characterized using ESI-MS and purified by
using high-performance liquid chromatography (HPLC). Cellular uptake study was
performed to determine binding specificity and internalization of two HER2 specific
peptides and cysteine-modified peptides (MARAKEC, MARSGLC). In vitro cell
viability assay was conducted to assess the cytotoxicity and determine the targeting
specificity as well as the potency of the peptide-drug conjugates.
The purity of each compound was greater than 90%. Internalization of both
HER2 specific binding peptides and cysteine-modified peptides were significantly
higher than random peptides in HER2 over-expressed cell lines, MDA-MB361 and
ZR75, while negligible uptake in HER2 negative cell line, HEK293. MC linked PDCs
showed similar cytotoxicity as peptide in all cell lines; while MC-VC linked PDCs
have higher cytotoxicity than MMAE in HER2 positive cell line and significant lower
cytotoxicity than MMAE in normal cell line HEK293. However, PDCs with MC link
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do not show significant difference in cytotoxicity compared to the peptide in all cell
lines.
In conclusion, specificity of HER2 binding for both peptides was preserved after
modification with cysteine.

The derivation of MMAE to link drug and peptide

played a crucial role in the anticancer activity.

Peptide-MMAE conjugates with

cleavable linker showed a promising targeting capability for delivery of MMAE to
HER2 overexpressed cancer cells.
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CHAPTER 1: INTRODUCTION

1.1. Cancer Therapy and Anti-cancer Drugs
According to the World Health Organization (WHO) statistics, 3/5 of death in the
world is attributable to cancer, diabetes, cardiovascular disease, and chronic
respiratory system disease; of these four categories of diseases, cancer is one of the
leading causes of death.
Several approaches to cancer treatment have been used for cancer therapy,
including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy,
hormone therapy, stem cell transplant, and precision medicine. Among them,
chemotherapy, hormone therapy, immunotherapy, and target therapy use anticancer
drug. Anti-cancer drugs can also be classified into four types based on the mechanism
and site of action, including the direct effects on DNA, drugs that disrupt its structure
and function; interference with DNA synthesis; antimitotic drugs; and drug
mechanism based on tumor biology.
1.1.1.

DNA-damaging Drugs

1.1.1.1. Alkylating Agents
Alkylating agents are a class of cytotoxic drugs that possess highly reactive
chemical properties. These molecules contain one to two alkyls groups, which can be
transformed into electron-deficient intermediate. These intermediate products
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covalently combine with DNA electrons in an alkylation reaction, resulting in the loss
of function of DNA in cell metabolism; thereby the cell composition is affected,
resulting in variation of cell division and, ultimately, cell death.
1.1.1.2. Platinum Compounds
Cisplatin is a nonspecific drug that when enters the cell cycle after internalization
into tumor cells and hydrolyzes the target molecule, such as cisplatin, carboplatin, and
oxaliplatin. This hydrolyzed complex interacts with DNA and forms a chelate ring
that results in the partial denaturation and loss of replicative capacity of the DNA [1].
Cisplatin also reacts with cellular proteins and RNA and forms inactive molecules
like glutathione and cysteine. Because of the rapid speed of proliferation and
synthesis in cancers, platinum compounds have a higher cytotoxic effect on cancer
cells than normal cells.
1.1.1.3. Bleomycin
Bleomycin is a glycopeptide antibiotic produced by Streptomyces verticillus that
causes DNA strand break by binding to DNA and inhibiting thymidine entry into
DNA. The breaking of DNA strands leads to the inhibition of DNA synthesis and cell
proliferation [2].
1.1.2.

Drug Interference with DNA Synthesis

Drug interference in DNA synthesis is also called as anti-metabolites, as it occurs
by the inhibition of DNA synthesis of folic acid, purine, pyridine, and pyridine
metabolism, thereby inhibiting the survival and replication of tumor cells, leading to
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tumor cell death. This kind of drug can be classified further into folic acid
antagonists.
1.1.3.

Antimitotic Drugs

Mitosis is a vulnerable stage in the survival of carcinoma cells, and therefore it
can be used to design drugs for anticancer intervention. Microtubule and associated
proteins play a vital role in the process of mitosis; microtubule-targeted drugs may
interfere with microtubule dynamics to activate the spindle assembly checkpoint
(SAC), induce mitotic arrest, and cause cell death ultimately [3]. There are two types
of

mitosis

drugs

according

to

the

mechanism

involved,

namely,

microtubule-destabilizing agents and microtubule-stabilizing agents [4]. Destabilizing
agents inhibit the polymerization of microtubules in high concentration, and most of
them

bind

to

the

taxoid-binding

domain

or

vinca

domain

[5].

Microtubule-stabilizing agents enhance microtubule polymerization, stabilize
microtubules, and prevent Ca2+ and subsequent disassembly [6].
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Microtubulestabilizing agents.

Figure 1.1 Four categories of anticancer drugs
1.2. Drug Delivery in Cancer
Anti-cancer drugs kill rapidly proliferating cells, which is not limited to cancer
cells only, resulting in side-effects such as hair loss, reduced blood cells, and stomach
irritation. However, discontinuation of drug therapy may result in cancer recurrence,
resulting in rapid proliferation of cells again [7]. In order to completely eradicate
cancer cells and reduce undesired side-effects, the strategy to deliver drugs to a target
tumor site has been proposed.
1.2.1.

Passive Target Delivery System

Passive targeting delivery system is designed to deliver the drug to the systemic
circulation by using the body's natural response to specific physicochemical
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characteristics. Rapid growing tumors generate new vessels or reroute the existing
vessels in order to adequate supply of nutrients and oxygen, [8] which causes
imbalance of angiogenic regulator, resulting in tumor vessel disorganization and
expansion, with a gap junction between the endothelial cells, thereby causing
enhanced permeability of the tumor vessel [9]. Because of the impaired clearance
system in the tumor tissues, macromolecules and lipids stay in the tumor interstitial
space for a long time [10]. This phenomenon is termed as tumor-selective enhanced
permeation and retention (EPR) effect of nanoparticles. The EPR effect has been
widely used to design passive-target delivery system because it meets the four
requirements of effective target drug delivery system, that is, retain, evade, target, and
release [11].
For obtaining abundant supply of nutrition and oxygen for the new vessels
generated, the rapidly growing tumor cells use glycolysis to obtain extra energy to
maintain their rapid metabolic rate, resulting in an acidic tumor microenvironment
[12]. Several approaches such as the use of pH-sensitive liposome have been used to
design pH-sensitive drug carriers that have stable physiologic pH (7.4), but which
degrade and release in the target tumor tissue with lower pH value [13].
pH-sensitive nanoparticles are devised to combine EPR effect and pH-trigger
release. The loaded drug accumulated in tumor via the EPR effect while remained
stable during blood circulation and released the encapsulated medications into acidic
environment provided by the solid tumor [14].
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1.2.2.

Active Target Delivery System

Active target delivery is designed to overcome the limited specificity of the
passive delivery system. This delivery system is based on the ligand–receptor
interaction that happens between delivery system and target when the delivery system
meets the target cells where there is efficient interaction between the ligands and
receptors [7]. For example, epidermal growth factor receptors (EGFR) are proteins
overexpressed on the surface of cells that can be used for targeting delivery via
specific ligand receptor interaction mechanism. To achieve efficient ligand–receptor
interaction, several factors should be considered: the extent and homogeneity of target
cell antigen or receptor expression, the availability of cell surface receptor on the cell
surface, the rate of drug release, and internalization.
1.3. Therapeutic Monoclonal Antibody
Monoclonal antibody is developed and designed to target overexpressed antigen
on or near the surface of malignant cells [15]. Therapeutic monoclonal antibody can
be used as a treatment option in several diseases such as oncology, inflammation,
cardiovascular diseases, and infectious diseases. Antibody exerts two important
functions, including binding and modulating antigen and binding complement and
immune-effector cells [16]. Tumor-targeting monoclonal antibody can be grouped
into six classes based on the functional consideration: (1) mAbs that inhibits the
intrinsic proliferation signal transduction pathway; (2) mAbs that activate the cell
surface cytotoxic receptors and then triggers apoptotic demise; (3) mAbs that binds
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tumor-associated antigens (TAAs) and exerts dependent antibody-dependent
cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis
(ADCP), and complement-dependent cytotoxicity (CDC) through innate immunity; (4)
immunoconjugates mAbs; (5) trifunctional or bispecific mAbs; and (6) mAbs that
interfere with nutrient transfer between tumor cells and stroma [17][18][19][20].
Although, in recent years, oncology therapeutic mAbs are developed at a fast
speed in preclinical and clinical trials, it remains common that antibodies do not alter
tumor growth when treated with xenograft mice model. To improve the therapeutic
effect, several approaches based on targeting cytotoxic agents on malignant tumor
cells by conjugation with antibody have been developed, including antibody
toxin-fusion proteins, antibody-drug conjugates (ADC), antibody enzyme conjugates,
and antibody radionuclide conjugate [21].
1.4. Antibody-drug Conjugates
1.4.1.

Pharmacological Mechanism of Antibody-drug Conjugate

Antibody-drug conjugates are composed of three basic parts: highly selective
antibody, linker, and cytotoxic small molecule drug. The structure of a typical ADC is
shown in Figure 1.
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linker

Drug

Antibody

Figure 1.2 Structure of typical antibody-drug conjugate
The objective to accomplish a well-designed ADC is that an ADC preferentially
delivers the cytotoxic small molecule drug only to tumor cells rather than to normal
cells in order to improve the therapeutic index [22][23]. The mechanism by which
ADCs disrupt tumor cells is by binding the specific mAbs to an antigen that is highly
expressed only on the surface of tumor cells. After binding to the antigen, an
ADC-antigen complex is formed, which is internalized into cells, and the cytotoxic
drug is released, leading to cell death [23]. A typical mechanism of antibody-drug
conjugates is shown in Figure 2.
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Antigen

Cell nucleus
Early endosome
1: DNA strand
breakage
2:Microtubule
distruption
Lysosome

Figure 1.3 Typical mechanism of antibody-drug conjugates internalization

1.4.2.

Design of Antibody-drug Conjugate

Based on the mechanism described above, three key procedures need to be paid
attention to when designing an ideal ADC: (1) antibody targets appropriate antigens
and forms an ADC–antigen complex, (2) the stable linker prior to reaching the target
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and releasing cytotoxic drug after internalization, and (3) the highly potent cytotoxic
drug should exert its pharmacological effect after reaching the target. . The selection
of an appropriate target, a stable linker, and a highly potent drug are discussed with
reference to the design principle of ADC as follows.
1.4.2.1. Target
An appropriate target selection should fulfill two criteria: high selectivity on
tumor cells and high internalization efficiency.
Most of the antigens express the same level on both normal cells and cancer
levels, which makes it difficult for the related antibody to recognize the cancer cells.
Therefore, an ideal target antigen should be expressed in higher copy numbers on the
tumor cells (overexpress); this overexpressed characteristic, in part, contributes to
ADC

efficacy

and

ADCs—brentuximabvedotin

tolerability

[23][24].

(ADCETRIS)

and

For

example,

two

trastuzumabemtansine

(T-DM1)—have been shown to achieve distinct clinical activities with overexpressed
target antigens on the tumor cells. ADCETRIS targeted antigen CD30 that is
expressed on normal cells and strongly expresses in systemic anaplastic large-cell
lymphoma (ALCL) and Reed–Sternberg cells of Hodgkin lymphoma (HL) tumor
cells [25]. Similarly, T-DM1 targeted antigen, HER2, with normal expression in
normal tissues, is highly overexpressed in some breast cancer tumors [26].
After binding to the antigen, the ADC conjugates with the antigen and forms an
ADC–antigen complex, which is then internalized into the tumor cells—this process
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is called as a receptor-mediated endocytosis. The extent and speed of internalization
of an ADC is depended on the nature of cell-surface receptors. Some receptors, like
transferrin receptors, continuously internalize without requiring binding with ligands,
whereas, receptors like epidermal growth receptor accelerate the internalization rate
after accumulate binding with their corresponding ligands [26]. In some cases, the
internalization of an ADC is much more efficient than that of an unconjugated
antibody [27][28].
1.4.2.2. Linker
A linker that connects monoclonal antibody with a cytotoxic drug binds through
covalent linkage. The stability of a linker is important because it stays stable in the
blood circulation while preventing damage to the non-target tissue, followed by
release of the drug after reaching the target site [22]. There are two main types of
linkers, including cleavable linker and non-cleavable linker; cleavable linker releases
drugs by enzymatic reactions or hydrolysis after internalization, while non-cleavable
linker releases drug through the degradation of antibody in the lysosome after ADC–
antigen complex internalization [23][24]. Table 1.1 lists some release mechanisms of
important linkers.
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Table 1.1 Release mechanisms of ADC linkers
Linker
Hydrazone
Peptide
Disulfide
Thioether

Release mechanism
Serum stable, degrade in acidic compartment within
cytoplasm
Enzymatically hydrolyzed by lysosomal protease like
cathepsin B
Cleavage through disulfide exchange with an intracellular
thiol
Nonreducible, intracellular proteolytic degradation

To optimize the solubility, the drug antibody ratio (DAR) and reduce the drug
resistance (the protein that transports cytotoxic agents out of the cells) of ADCs,
several strategies have been proposed including induce bystander effect and the use of
polar linkers.
Solid

tumors

express

antigen

heterogeneously,

whereas,

a

positive

antigen-specific ADCs only kills antigen-positive cells, which is ineffective in
eradicating tumors. Therefore, an effective ADC should kill not only antigen-positive
cells but also the surrounding cells through the bystander effect. Bystander effect
depends on the charge of the linker-drug derivation released from ADCs, for example,
the ADC brentuximabvedotin release neutral-charge MMAE, cross bio-membranes,
and kill bystander epithelial cells, whereas ADCs based on MMAF release a charged
metabolite, which is difficult to pass through bio-membranes and kill the neighboring
cells. Reducible cleavable disulfide linkers can cross bio-membranes, while
non-reducible thio-ether linkers cannot, which indicates that the ADCs with disulfide

30

linker have bystander cytotoxicity, while ADCs with thio-ether linker do not.
MDR1 is a protein that transports hydrophobic cytotoxic agents out of cells, and,
as a result, hydrophobic agents like ADCs with non-charged or non-polar
maytansinoid linkers prove to have lower efficiency to MDR-positive cells.
Development of an ADC with a polar or charged linker would not only overcome the
adverse effect of MDR but also improve the solubility and therapeutic index. Because
reducing hydrophobicity can slow down the clearance and enhance pharmacokinetics
[25].
1.4.2.3. Cytotoxic Drug
Low-potent cytotoxic agents such as doxorubicin and mitomycin used in the early
ADC developments were found to be inefficient in inhibit solid tumor growth and
showed lower accumulation in the target cells [29]. The reason for the failure of the
conventional cytotoxic agent ADC could be attributed to only a limited number of
antigens are expressed on the tumor surface, and the amount of drugs delivered to the
tumor cell surface is low for a low drug to antibody ratio (DAR 3.5:4). Hence, only a
limited number of novel highly potent cytotoxic agents with IC50 of 10-10-10-12M have
been chosen to develop ADCs. Most of them target DNA or microtubule. The drugs
targeting DNA are cytotoxic for both proliferating and non-proliferating cells, while
drugs targeting microtubules are cytotoxic only for the proliferating cells [30]. When
cytotoxic agents are chosen for developing ADCs, several factors should be
considered, such as (1) most of the cytotoxic agents are hydrophobic, which can
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induce antibody aggregation, and therefore lead to increased clearance rates and
shortened validity [31]. (2) When a drug structure is modified for the linkage of the
conjugate, the potency may decrease, and water solubility and stability may change
[32]. Table 1.2 lists the current ADCs in clinical trials.
Auristatins and maytansionid are two typical groups of cytotoxic agents used
in ADC developments. Auristatins have two derivatives: monomethyl auristatin E
(MMAE) and monomethyl auristatin F (MMAF), which derived from the natural
antimitotic agent dolastatin 10 and exerted their effects by inhibiting tubulin
assembly.
In maytansinoid ADC, drugs used in the clinical trial are DM1 and DM4,
which derived from natural benzoansamacrolide product maytansine, and it acts on
tubulin. Due to its high toxicity, it has failed in clinical trials as an independent
anticancer drug, but its stability and acceptable solubility make it a candidate for use
as cytotoxic agent in ADC [33].
Other cytotoxic agents that have been used to develop ADCs include
indolino-benzodiazepine,

irinotecan

derivatives,

duocarmycins,

pyrrolobenzodiazepines (PBDs), and tubulysins. Tubulysins are antimitotic peptides
that inhibit microtubule polymerization during mitosis, which results in cell death.
Duocarmycins is a DNA groove-alkylating agent. It binds to the minor groove of
DNA and destroys it at a specific site [34][35]. PBDs, natural anticancer antibiotics
that bind to the minor groove of DNA and destroy DNA in a specific sequence, are
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now fast becoming as popular as ADCs development candidates for at least 10 ADCs
based on PBDs have entered clinical trials.

Table 1.2 ADC drugs in clinical stage
Cytotoxic
Clinical stage
class
Phase
II
MMAE
(stopped)
Phase
II
MMAE
(stopped)
Phase
I
MMAF
(stopped)
Entered market
DM1
in 2013

Drug

Target

Linker

Pinatuzumabvedotin

CD22

VC

Indusatumabvedotin

GCC

VC

Vorsetuzumabmafodotin

CD70

MC

Trastuzumabemtansine

HER2

SMCC

Mirvetuximabsoravtansine

FOLR1

sulfo-SPDB DM4

Anetumabravtansine

Mesothelin SPDB

DM4

Phase II

SAR428926
ADCT-301

LAMP1
CD25

SPDB
PEG8-va

DM4
SG3199

Phase II
Phase I

Rovalpituzumabtesirine

DLL3

PEG8-va

SG3199

Phase III

IMGN779

CD33

sulfo-SPDB DGN462

Gemtuzumabozogamicin

CD33

Hydrazone

CM1

Inotuzumabozogamicin

CD22

Hydrazone

CM1

Pre-registration

Trastuzumabduocarmazine HER2++

vc–seco

DUBA

Phase I

RC48-ADC

HER2

VC

MMAE

Phase I

Sacituzumabgovitecan

TROP2

CL2A

SN38

Phase III

Vadastuximabtalirine

CD33
VA
Engineered

Phase III

Phase I
Approved
Japan

SGD1882 Phase III

in
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1.4.3.

Other Optimized Approaches of Antibody-drug Conjugates

Apart from selecting an appropriate antibody, linker, and cytotoxic agents,
several additional approaches have been proposed to optimize ADC based on
increased tumor penetration and antibody binding to inhibit immune checkpoints.
Due to the poor penetration into solid tumors by antibody, there is a limit (0.001–
0.01% of injected amount per g) to which the cytotoxic agents can reach and target
tumor cells in vivo [36]. Based on this limitation of ADCs, several new designs have
been generated for the next generation ADCs, including (1) non-internalizing mAbs
that link cytotoxic agents with disulfide linkers that are cleaved in a specific tumor
extracellular microenvironment [37] and (2) Non-lgG scaffold includes designed
Ankyrin Repeat Proteins (DARPins) [38]. Both design approaches demonstrated
improved pharmacological and therapeutic performance.
Another attractive way to improve the potency of ADCs is by combining it with
immune-oncology antibodies. Antibodies that target immune checkpoint inhibitors
like programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1
(PDL1), and immune responses like cytotoxic T lymphocyte 4 (CTLA4) have
surprising efficiency on a series of tumor types. Checkpoint inhibitors activate
immune responses without antigen-specific, seems to be active in a variety of tumors
mutations, meanwhile, some cytotoxic agents used in ADCs have been shown to
induce the death of immunogenic cells and induce activation and maturation of
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dendritic cells. Hence, a combination therapy by immune-checkpoint inhibitors with
ADCs that increase the immune response may have spectacular effect on oncology
therapy [39].
1.5. Peptide-drug Conjugates
Peptide-drug conjugates (PDCs), like ADCs, are another class of prodrugs.
Targeting delivery of a drug to particular tumor-surface receptors is achieved by
conjugating a drug to a specific sequence peptide. Peptide-drug conjugates are
composed of three parts: drug, linker, and peptide (Figure 2). Due to the short length
of peptide, PDCs are biodegradable and can avoid undesired immunogenic responses
[40],[41]. The diversity of sequence made the diversity application of PDCs, while
different sequences elicit different hydrophobicity and ionization, which could
influence bioavailability both in vitro and in vivo. Other than ADCs, the low
molecular weight of peptide allows PDCs high purification by using HPLC. Based on
the difference in the characteristics of peptides, PDCs can be separated into two
categories: Cell-targeting peptide drug conjugates and cell-penetrating peptide-drug
conjugates.

Drug

Linker

Peptide

Figure 1.4 Structure of peptide-drug conjugate
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1.5.1.

Cell-targeting Peptide-drug Conjugates

Tumor targeting peptide-drug conjugates are designed by using peptide with
binding specificity to deliver the drug to particular tumor cells or tissues. The tumor
targeting peptides were generated to target receptors expressed on the surface of the
tumor vascular endothelial cell and cancer cell, or target to the tumor’s extracellular
matrix [42]. The following sessions list some categories of cell-targeting peptides that
have been used to developed peptide-drug conjugates.
1.5.1.1. IntegrinTtargeted Peptide–drug Conjugates
Integrins are a family of proteins that are widely used as receptors because they
are widely expressed in numerous cells. They play vital roles in physiological
development, maintenance, repair of tissues, and pathological process in diseases,
especially in cancer [43]. In the past two decades, integrin-targeted peptide-drug
conjugates have been developed based on the wide distribution of αvβ3 targeting
Arg-Gly-Asp (RGD) motif. Our group previously reported the potential of using
modified RGD peptide amphiphiles to deliver hydrophobic drug like methotrexate,
paclitaxel [42][44][45][46]. The Wadih group [47] conjugated RGD4c to doxorubicin,
displaying enhancement of tumor inhibition and less toxicity of PDC to the liver and
the heart compared with free doxorubicin. Another research group proved that when
conjugated to integrin-targeting peptides, doxorubicin is preferentially released in
tumor cells, which explains the unknown problem that the reported effect stems from
the PDCs or the released doxorubicin. Except doxorubicin (DOX), paclitaxel (PTX)
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and camptothecin (CPT) have also been used to conjugate with integrin-targeting
peptides, both of which reveal high antitumor effect than free drugs in in vitro studies
[48][49][50].
1.5.1.2. Hormone Analog Peptide-drug Conjugates
Hormone receptors like gonadotropin-releasing hormone (GnRH) receptor and
somatostatin receptors are particularly overexpressed on the membrane of tumor cells
[51]. Gonadotropin-releasing hormone (GnRH) receptor also named luteinizinghormone-releasing hormone (LHRH) receptor is not expressed in critical organs.
LHRH are being developed as conjugated to selectively deliver cytotoxic agents to
cells expressing LHRH receptors [52]. Liu et al. conjugated luteinizing
hormone-releasing hormone (LHRH) agonist AEZS-108 with anti-cancer agent,
doxorubicin to targeted deliver doxorubicin selectively to prostate cancer CTCs,
which has entered into clinical phase I study [53]. Tomas Vanek successfully
developed targeted delivery system by conjugating mitotic inhibitor Paclitaxel and
GnRH analog peptide (pGlu–His–Trp–Ser–Tyr–Gly–Leu–Arg–Pro–Gly·NH2) [54].
Somatostatin, also known as growth hormone- inhibiting hormone, is a cyclic
polypeptide that controls endogenous inhibitory [55]. Somatostatin is broadly
distributed in the nervous system, regulates cell proliferation and division by directly
activating somatostatin receptors [56]. The somatostatin belongs to G protein-coupled
receptors family, and there are five subtypes of somatostatin have been identified.
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Among them, somatostatin receptor-2 is preferential overexpressed in many tumors
and tumor blood vessels. Hence, most of the somatostatin analog conjugates were
developed to target to somatostatin receptor 2 site [57]. Huang et al. produced
paclitaxel conjugate with somatostatin analog octreotide via a succinate linker[58].
This taxol octreotide conjugate was found to trigger apoptosis of somatostatin
expression cells MCF-7 [58].
1.5.1.3. Other Cell-targeting Peptide-drug Conjugates
In addition to RGD peptides and hormone analog peptides, other cell-targeting
peptides were studied to develop new peptide-drug conjugates. EphA2 is
tumor-targeting receptors that observed overexpressed on the surface of specific solid
tumor cells including breast, prostate, and pancreatic. Ahmed F. Salem et al.
generated peptide-drug conjugate by coupling EphA2-targeting peptide 123B9 with
paclitaxel [59]. In breast cancer models, EphA2-targeting PDCs were found to
efficiently inhibit carcinoma metastasized to the lung. PDCs that target to HER2
receptors was performed, Tai group utilize HER2 targeting peptide KCCYSL linked
to anticancer agent TGX-221 via self-cyclizing linkage. The conjugate turned out to
specified bind to the HER2 receptor expressed on prostate cancer cells surface and
provide a promising treatment strategy for prostate cancer [60].
1.5.2.

Cell-penetrating Peptide-drug Conjugates

Cell penetration peptides (CPPs) are types of peptides that are able to cross the
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mammalian cell membrane through the receptor-independently way. The rapid speed
that CPPs enter into cells made CPPs attractive cargo to deliver therapeutic agents
like a drug, DNA to the various situation and biological system [61]. Marco Lelle
group synthesized two doxorubicin cell-penetrating peptide conjugates through
hydrazone linker. The cellular uptake and distribution were assessed in MCF-7 and
HT29 cell lines, and the increased toxicity on breast cancers has been observed on
both two PDCs compared to HT29 cells [62]. Duan group developed two paclitaxel
(PTX) cell-penetrating peptide conjugates PTX-TAT and PTX-LMWP. The enhanced
antitumor potency was observed in tumor-bearing mice [63]. The anticancer agent
gambogic acid (GA) has been developed to link with cell penetration peptide TAT.
The improved solubility and induced EJ bladder cell uptake, toxicity and apoptosis
were observed, which provide a promising used in bladder cancer therapy [64].
1.6. Anticancer Peptides (ACPs)
In addition to conjugating anti-tumor cytotoxic drug with targeting antibody or
peptide, anticancer peptide has become new treatment option for the molecular target
anticancer drug development. Anticancer peptides are mostly derived from
antimicrobial peptides (AMPs), which are a part of the immune defense mechanism of
several organisms. The reason that AMPs can be used as ACPs for cancer therapy is
because of the same membrane characteristic (negative cell surface charge) of the
cancer cell and bacterial cells [65][66]. ACPs can be divided into two categories:
membranolytic and non-membranolytic [67].
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The selectivity and toxicity of peptide with membranolytic mechanism are
modulated by target membrane feature [68]. The first difference between cancer cells
and normal cells is the negative charge in the membrane disperse anionic molecules
like

phospholipid

phosphatidylserine

(PS),

sialylated

gangliosides,

and

O-glycosylated mucins in the membranes of cancer cells, resulting in a contrasting
negative charge compared to the normal mammalian cell. Another difference between
cancer cells and normal cells is in the content of cholesterol, as normal cell
membranes have a high content of cholesterol in order to protect the cell by
modulating the cell fluidity and block the entry of cationic peptides while most cancer
cell surface cannot [69].
By this membranolytic mechanism, the peptide action events include permeation,
swelling of mitochondria, and apoptosis [69]. Peptides regulate the tumor vasculature
by blocking the receptors that on the angiogenic endothelial cells. The formation of
tumor vasculature is perturbed via this non-membranolytic mechanism [70][71].
There are a total of 202 anticancer peptides recorded in the APD databases. Table
3 shows some of the anticancer peptides that possess anticancer activity. Peptides can
also be divided into two main groups based on the tumor type: solid and
hematological tumors.
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Table 1.3 List of anti-cancer peptides
Peptide name

Sequence

Anticancer
Tumor type
activity
Necrosis
via
Solid,
membrane
Hematological
depolarization
ROS
Solid
production and cell
membrane
lysis
with possible pore
formation
in
mitochondria
ROS
Solid
production and cell
membrane
lysis
with possible pore
formation
in
mitochondria and
Cell membrane
Solid
disruption
with
probable
pore
formation
Cell membrane
Solid
lysis

D-K6L9

LKLLKKLLK
KLLKLL

NRC-03

GRRKRKWL
RRIGKGVKIIGG
AALDHL

NRC-07

RWGKWFKK
ATHVGKHVGKA
ALTAYL

Polybia-MPI

IDWKKLLDA
AKQIL

Hepcidin-TH2-

QSHLSLCRW
CCNCCRSNKGC

Temporin-1CE

FVDLKKIANI
ROS
INSIF
production,
membrane
disruption, calcium
release,
GFIFHIIKGLF
Cell membrane
HAGKMIHGLV
lysis mediated by
necrosis inhibitory
activity

3

a

Epinecidin-1

Solid

Solid

Cancer cell
Human prostate

Human breast

Human breast

Human bladder
and prostate

Human cervix,
hepatocellular
carcinoma,
fibrosarcoma
Human breast

Human lung,
cervix,
hepatocellular
carcinoma
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PTP7

FLGALFKAL
SKLL

Apoptosis
induction

Solid

BEPT II

RAALAVVL
GRGGPR

Apoptosis
induction

Solid

ERα17p

PLMIKRSKK
NSLALSLT

Apoptosis
induction
and
massive necrosis
RRRRRRRGG
Plasma
KLAKLAKKLAK membrane
LAK
permeabilization by
pore formation
IWIAQELRXI
Apoptotic
GDXFNAYYARR resistance

Solid

SK84

AAGAATTC
AGCCAGCTAGG
TGACTTG

Membrane
disruption

Hematological

LfcinB

FKCRRWQW
RMKKLGAPSITC
VRRAF

Apoptosis by
direct disruption of
the mitochondrial
membrane

Hematological

R7-KLA

BIM SAHBA

1.6.1.

Human lung,
prostate, breast and
hepatocellular
carcinoma
Human
prostate
Human breast

Hematological

Human acute T
cell leukemia

Hematological

Human
histiocytic
lymphoma, chronic
myelogenous
leukemia,
acute
myeloid leukemia
Human
leukemia, liver and
breast
Human acute
lymphoblastic
T
leukemia, acute T
cell leukemia

Lytic Peptide

Lytic peptides are a group of bioactive cationic peptides that act on the surface of
cell membranes and have strong anti-cancer activities [72]. As the multidrug
Resistance (MDR) resulted in reduced efficiency in the cancer cells when treated with
the cytotoxic agents, the development of lytic peptide is attractive for its ability to
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bypass MDR mechanism by acting on the cell membrane [73].
K6L9, a typical lytic peptide, induces cytolytic effect through these two steps: (1)
membrane disruption and necrosis of tumor cells and (2) decrease in the tumor vessel
density. It can inhibit the metastases for both solid tumor and hematological tumor
when they are used in treatment in vivo [74]. By targeting with phospholipid
phosphatidylserine (PS) expressed on the neoplastic cells, the peptide colocalizes with
the negatively charged phospholipid and then elicits membrane-depolarizing lytic
activity.
Consider the lower extracellular pH in the solid tumor site as compared to the pH
in the normal tissue site, the pH-sensitive lytic peptide has raised interest. Liang et al.
[80] designed a pH-sensitive lytic peptide by modifying a known lytic peptide LL-1
(FLGALWKALSKLL) with histidine (H) amino acid, and then found more
pH-sensitive activity on histidine-containing peptides LL-1a, LL-1b, and LL-1c
(FLGALWHALSKLL, FLGALWKALSHLL, FLGALWHALSHLL) [73]. Another
advantage of histidine-containing peptides represents improved stability and half-lives
(up to 11 h) [72].

1.6.2.

Hybrid peptide

Although lytic peptide has its selectivity for tumor cells, a new strategy has been
proposed, wherein antigen-targeting peptide is combined with lytic peptide to form a
hybrid peptide for use in assessing the better selectivity and cytotoxic activities in
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vitro and in vivo. In 2013, Kawakami et Al. [75]designed a HER2-lytic hybrid peptide
by linking the HER2-binding moiety peptide KCCYSL and a newly designed lytic
peptide KLLLKLLKKLLKLLKKK (bold letters indicate D-amino acids) and
achieved significant inhibition of HER2 receptors and block the HER2 signal in the
HER2 overexpressing cell lines. In vivo studies also proved the efficiency of
HER2-lytic hybrid peptides [75]. In 2016, the Kawakami group [76] prepared a new
hybrid peptide based on the EGFR binding moiety, that is, EGFR-lytic hybrid peptide,
which elicited cytotoxic effect on the pathophysiology of esophageal squamous cell
carcinoma. Table 1.4 shows some of the hybrid peptides that have been developed. It
is worth suggesting that conjugating hybrid peptide with cytotoxic drug may help
reverse drug assistance and induce efficiency of cytotoxic agents.

Table 1.4 List of hybrid peptides
Target
EGFR

Target peptide
YHWYGYTPQNVI

Lytic peptide
KLLLKLLKKLLK
LLKKK

Hybrid peptide
YHWYGYTPQNVIGGGKL
LLKLLKKLLKLLKKK

HER2

KCCYSL

KLLLKLLKKLLK
LLKKK

KCCYSLGGG
KLLLKLLKKLLKLLKKK

αvβ3

CIRTPKISKPIKFELS

SKKPVPIIYCNRRS
GSKKPVPIIYCNRRSGKCQ
GKCQRM
RMGSIRTPKISKPIKFELSG
[78]
MPKKKPTPIQLNP
HAIYPRHGGCGMPKKKPT
PIQLNP [79]

G
TfR

HAIYPRH
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1.7. Human Epidermal Growth Factor Receptor 2
The ErbB family is a group of proteins containing four receptor tyrosine kinases,
including epidermal growth factor receptor (EGFR), HER2 (ErbB2), HER3 (ErbB3),
and HER4 (ErbB4). The ErbB receptors play an important role in human cancers
because they are expressed in multifarious tissues of epithelial and neuronal origin
[77]. After ligand binding with the receptor, the pathways will be activated.
Consequently, the cancer cells show higher proliferation, survival, migration, and
differentiation potential [78][79].
The human epidermal growth receptor 2 oncogene encodes a receptor tyrosine
kinase that is overexpressed in >20% of human breast cancer cases [80]. HER2 has
become a suitable target candidate for molecular target cancer therapy. Humanized
recombinant monoclonal antibodies that inhibit HER2 receptors have also been
developed, including trastuzumab and pertuzumab, which have been used for the
treatment of HER2-positive breast cancers [81]
Except antibodies, peptides that target HER2 receptor tyrosine kinase have also
been developed. Table 5 shows the HER2-targeting peptides derived from the phage
display library.
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Table 1.5 Sequence of HER2-targeting peptides
Peptide sequence

Library

Referen
ce

AC#SLQDPNC#DWWGHYC#G (H8)c
ACGLQGYGCWGMYGKCG (H30)c
CVGVLPSQDAIGIC (L-26-19)d
CGPLPVDWYWC (L-26-24)d
CEWKFDPGLGQARC (N-12-1)e
CDYMTDGRAASKIC (N-12-2)e
KCCYSL
MARSGL, MARAKE, MSRTMS
LTVSPWY
WTGWCLNPEESTWGFCTGSF (EC-1)

ACX6CX6CG
ACX6CX6CG
Ph.D.-12
Ph.D.-12
Ph.D.-12
Ph.D.-12
6mer
6mer
Ph.D.-7
20mer

[88]
[88]
[89]
[89]
[89]
[89]
[90]
[91]
[92][93]
[94]

1.8. Statement of the Problem
In the background section, we have listed novel target-delivery system and
among them, the HER2-targeted antibody-drug conjugate Kadcyla (trastuzumab
emtansine) was developed and approved by FDA in 2014. However, the poor
penetration in solid tumor, the high manufacturing cost, and long development cycle
limits the extensive development of antibody–drug conjugates. Compared to the
antibody, peptides with flexible structure and low molecular weight are becoming a
promising target agent for application in the target delivery system.
1.9. Hypothesis
Designed HER2-targeting peptide–drug conjugates and hybrid peptides could
exhibit highly selective cytotoxicity for HER2 overexpressed breast cancer cells.
1.10.

Specific Aims

The objective of this research is to design the potent peptide–drug conjugates and
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hybrid peptides that provide a prospective chemotherapy strategy for breast cancer
patients. In order to achieve this objective, the following specific aims have been
established:
1.

To synthesize HER2-targeted peptides using solid phase synthesis method on
Wang resin.

2.

To study the in vitro binding specificity of Her2-targeted peptides and
cysteine-modified peptides.

3.

To design and synthesize peptide–drug conjugates with a non-cleavable linker
maleimidocaproyl (MC) and MMAE.

4.

To design and synthesize peptide–drug conjugates with a cleavable linker
maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (MC-VC-PAB)
and MMAE

5.

To synthesize hybrid peptides with a cytolytic peptide Melittin
(GIGAVLKVLTTGLPALISWIKRKRQQ).

6.

To purify and characterize peptides and peptide–drug conjugates.

7.

To study the cytotoxic potency of synthetic peptide–drug conjugates and hybrid
peptides.
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CHAPTER 2:

SYNTHESIS AND CHARACTERIZATION OF PEPTIDES

2.1. Introduction
A typical peptide synthesis requires the formation of amide bond, provided and
formed by the amino and carboxyl groups of two amino acids. However, numerous
possibilities of combinations of amino acids made the synthesis of peptide more
complicated than forming a simple amino acid. Solid-phase peptide synthesis (SPPS)
technique was developed in 1962 by Bruce Merrifield in order to provide an effective,
rapid, and simplified method for the preparation of peptides and small proteins. The
basic concept of SPPS is the step-wise construction of a peptide chain attached to an
insoluble polymer substrate. The insoluble polymers used for SPPS also named resins.
Different resins can be used to synthesize various peptides. For example, Wang resin
is conventional resin for Fmoc/tBu SPPS; DHPP Resin is developed especially for
peptides with C-terminal proline; PDDM-resin is applied for peptides containing
C-terminal Cys or His. 2-Chlorotrityl is an acid-labile resin. This resin is suitable for
synthesizing peptides containing a C-terminal Cys or Pro. [82]. The insoluble polymer
resin attached to the carboxyl group of the terminal amino acid conjugates to the next
amino acids protected by the Fmoc group. After coupling, the Fmoc acid protection
group is removed from the chain in order to provide a free amino group for coupling
the next amino acid. The peptide chain is extended by the duplication of synthesis
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cycle. The polymer resin and the side-chain protection group must be removed prior
to the cleavage of resulting peptide by using a 95% solution of trifluoroacetic acid
(TFA).
The purpose of this chapter is to utilize solid phase peptide synthesis technique to
synthesis HER2 targeting peptides for binding specificity study and PDC synthesis.
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Figure 2.1 Mechanism of piperidine de-protection
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Figure 2.2 Mechanism of coupling
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Figure 2.3 Mechanism of cleavage
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Figure 2.4 Mechanism of synthesis FITC-labeled peptide
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2.2. Materials
Fmoc-Wang resins, N-hydroxybenzotriazole (HOBT),
N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate
(HBTU), triisopropylsilane (TIS) were obtained from Chem-Impex International Ltd.
(Wood Dalw, IL, USA). Acetonitrile (ACN), dichloromethane (DCM), and 5-FITC
were purchased from Fisher Scientific (Pittsburgh, PA, USA). Diisopropylethylame
(DIPEA), tert-butyl methyl ether, trifluoro acetic acid (TFA), and
N,N’-dimethylformamide (DMF) were obtained from Axros Organics (New Jersey,
USA). All amino acids used in the SPPS were purchased from Anaspec Int. (Fremont,
CA)
2.3. Methods
2.3.1.

Synthesis of Peptides

Peptides were synthesized by SPPS with Fmoc chemistry on Wang resin (0.2
mmol) and coupled amino acids (1 mmol) with DIPEA (1.8 mmol), HBTU (1 mmol),
and HOBT (1 mmol). After coupling for 2.5 h at the room temperature, Kaiser test
was performed to ensure the completion of the reaction. Fmoc group deprotection
solution was prepared with 20% piperidine in DMF. Peptide cleavage cocktail was
performed with phenol (0.33 g), deionized water (330 µL), TIPS (60 µL), and TFA
(5.7 mL). After shaking for 3 h at the room temperature, the TFA solution was cooled
and collected by using nitrogen. The peptide was then precipitated by adding cold
tert-butyl methyl ether. The resultant peptide precipitate was washed three times with
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cold ether, dissolved in water, and then lyophilized overnight.
2.3.2.

Synthesis of FITC-labeled Peptides

The 6-aminohexanoic acid protected with Fmoc was coupled to peptide with
resin by using the same method as that for regular amino acid. 5-FITC (0.3 mmol)
was conjugated with peptide (0.1 mmol) in anhydrous DMF solution catalyzed with
DIPEA (1.2 mmol). The reaction was performed at the room temperature for 12 h in
dark. The FITC-labeled peptide was removed from the resin by using the same
cocktail as mentioned above and following the same washing, precipitating, and
lyophilizing procedures used in 2.3.1. Dried FITC-labeled peptide was stored at -20°C
for further use.
2.3.3.

HPLC Analysis and Purification

The peptides and FITC-labeled peptides were analyzed by reverse-phase
high-pressure liquid chromatography (HPLC) using the Agilent 1100 System with
Agilent Zorbax SB-C18 (4.6 x 150 mm, 3.5 µm column) at 210 nm and 230
wavelengths. The mobile phase solvents were water (solvent A) and acetonitrile
(solvent B), and both the solvents were used with 0.1% TFA. Elution was performed
with a liner gradient for 30 min from 5% to 95% solvent B at the flow rate of 1
mL/min. The peptide was purified by collecting the eluting peak, lyophilizing, and
then storing at -20°C for further use.
2.3.4. Characterization of Peptides
The peptides were characterized by using the Electro Spray Ionization Mass
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Spectrometry (ESI-MS; AB Sciex PI 3000 Ion Trap Mass Spectrometer, SCIEX, CA,
USA) . The samples were prepared in acetonitrile and water mixtures and were
infused at the speed of 10 µL/min. Ion source parameters are listed as follows:
Nebulizer Gas (NEB) 8 Psi,  IonSpray Voltage 5500 V; TEM （Temperature） 300℃;
CUR （Curtain Gas） 8 Psi.
2.4. Results and Discussions
Peptides were successfully synthesized using SPPS technique. To make the
coupling reaction more efficient, a potent coupling agent, a mixture of HOBT, HBTU,
and DIPEA, was used. Fluorescent-dye FITC was conjugated with the peptides for
confocal studies. The peptide cannot be directly linked to the FITC because of the
unstable abilities of conjugates. To prolong the stability of the conjugates, a spacer,
6-amino hexanoic acid, was attached to the N-terminus of the peptide and then
conjugating FICT on the spacer.
The HPLC peaks of all peptides were observed at around 8–9 min (Figures 2.15
to 2.18). HPLC peaks of FITC-conjugated peptides were observed at 15–16 min
(Figures 2.19 to 2.22). Different peaks were collected to identify and confirm the
molecular weights of peptides and FITC-labeled by MS. All the peptides were
characterized using ESI MS. The MS results revealed the expected molecular weight
of the peptides and FITC-labeled peptides. The MS confirmed the formation of all
peptides and FITC-labeled peptides molecules as shown in Figures 2.5 to 2.14 and
table 2.1.
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HER2 targeting peptides and cysteine modified HER2 targeting peptides were
successfully synthesized for the further peptide binding specificity study and
peptide-drug conjugates synthesis.
The HER2 targeting peptide has been reviewed in 1.7. Among the peptides listed
above, the peptide MARAKE and MARSGL have been chosen to develop
peptide-drug conjugates. These 6-mer peptides with published binding constant (KD)
value 10 nM [83], were ideal candidates to for PDC synthesis. The equilibrium
binding constant (KD) is generally used to determine the binding affinity between the
ligand and the receptor. Binding affinities are used to determine the strength of
binding of a single molecule to its receptors. The KD value relates to the
concentration of antibody. The lower KD value represents the higher affinity of the
antibody or antibody mimic. Peptides cannot be used directly to conjugate to drugs
without linkage.
In our study, the reaction between peptides and linker rely on a thiol group
reacting with the maleimide group, which will be further discussed in Chapter 4.
Thiol group was provided by cysteine in the peptide, while maleimide group comes
from maleimidocaproyl to form the linker. As described above, cysteine modified
peptides (MARAKEC, MARSGLC) have been synthesized for PDC synthesis.
To further prove the binding specificity of the chosen HER2 targeting peptide and
cysteine modified HER2 targeting peptides, FITC-labeled peptides were synthesized
for immunofluorescence in-vitro study. Scramble peptide (MAKRAE) and
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FITC-labeled scramble peptide were developed as the negative control in
immunofluorescence study.
All peptides were successfully synthesized by SPPS. FITC was conjugated to the
peptides at the N-terminus. All peptides molecules were characterized by MS and
purified by RP-HPLC for use in further experiments.
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Table 2.1 Sequence of synthesized peptides
Peptides
ER1
FITC-ER1
ER1C
FITC-ER1C
ER2
FITC-ER2
ER2C
FITC-ER2C
RA1
FITC-RA1

Structure
MARAKE
MARAKE-FITC
MARAKEC
MARAKEC-FITC
MARSGL
MARSGL-FITC
MARSGLC
MARSGLC-FITC
MAKRAE
MAKRAE-FITC

HPLC Purity
94.00%
96.00%
95.00%
99.90%
97.00%
99.80%
96.00%
96.10%
94.00%
95.10%

MW
704.84
1206.00
807.99
1309.99
633.76
1135.76
736.91
1238.00
704.84
1206.00
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Figure 2.5 The ESI-MS spectrum of peptide ER1
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Figure 2.6 The ESI-MS spectrum of FITC-labeled peptide ER1
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Figure 2.7 The ESI-MS spectrum of peptide ER1C
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Figure 2.8 The ESI-MS spectrum of FITC-labeled peptide ER1C
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Figure 2.9 The ESI-MS spectrum of peptide ER
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Figure 2.10 The ESI-MS spectrum of FITC-labeled peptide ER2
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Figure 2.11 The ESI-MS spectrum of peptide ER2C
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Figure 2.12 The ESI-MS spectrum of FITC-labeled peptide ER2C
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Figure 2.15 The HPLC chromatogram of peptide ER1

Figure 2.16 The HPLC chromatogram of peptide ER1C
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Figure 2.17 The HPLC chromatogram of peptide ER2

Figure 2.18 The HPLC chromatogram of peptide ER2C
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Figure 2.19 The HPLC chromatogram of FITC-labeled peptide ER1

Figure 2.20 The HPLC chromatogram of FITC-labeled peptide ER1

Figure 2.21 The HPLC chromatogram of FITC-labeled peptide ER2
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Figure 2.22 The HPLC chromatogram of FITC-labeled peptide ER2C

73

CHAPTER 3:

BINDING SPECIFICITY OF HER2-TARGETING PEPTIDE

3.1. Introduction
The signaling pathway in cells starts from the binding of ligands and receptor.
Ligand and receptor come in closely matched pairs, with receptors recognizing
specific ligands. Another similar signaling pathway is antibody-antigen interaction.
The antibody specifically binds to the antigen expressed on the surface of cells. After
binding with an antigen, the antibody-antigen complex is transported into cells. The
design of antibody-drug conjugates utilizes this characteristic of antibody and antigen
complex. By linking the drug to an antibody, the conjugate can deliver the drug to the
specific target cancer cells. The specificity of antibody leads to high potency and low
cytotoxicity of antibody-drug conjugate, the same concept can be applied to the
peptide-drug conjugates.
Immunofluorescence (IF) is a conventional laboratory technique used to identify
microbiological samples with a fluorescent microscope. This technique is used for
studying specificity of antibodies binding to a specific antigen by monitoring
fluorescent dyes in specific bio-molecular targets or cells. Immunofluorescence
labeled antibody can recognize and stain particular cellular protein. The specificity of
the antibody-fluorescence conjugation can be verified by using cell line with known
expression target or level. The specificity of peptides can be determined by similar
method with the use of fluorophore-conjugated targeting peptides. HER2 is
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overexpressed in breast cancer cell lines, and it undergoes receptor-mediated
endocytosis when trastuzumab binds to HER2. To evaluate the peptides’ binding
specificity to HER2 receptor, confocal and fluorescent microscopy was used with
5-FITC conjugated HER2-targeting peptides. Fluorescent microscopy showed the
binding specificity, while confocal microscopy confirmed the internalization of the
samples.
The purpose of this chapter is using immunofluorescence to verify the specificity
of HER2-targeting peptide.
3.2. Materials
The Alexa Fluor 594 wheat germ agglutinin SlowFade were obtained from
Invitrogen (Carlsbad, CA, USA). Formaldehyde (4%) in PBS was purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). All chemicals and solvents
were used without purification. PBS was ordered from Gibco (Invitrogen Corporation,
Japan).
The MDA-MB 361, ZR 75, and HEK 293 cells were purchased from ATCC
(Manassas, VA, USA). Dulbecco’s modified eagle medium (DMEM), 4.5 g/L glucose,
L-glutamine and 1% penicillin-streptomycin (5000 I.U./mL) were obtained from
Mediatech (Manassas, VA, USA). Sodium pyruvate containing 10% heat-inactivated
fetal bovine serum was ordered from Gemini (Sacramento, CA, USA)
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3.3. Methods
The MDA-MB 361, ZR 75, and HEK 293 cells were cultured in 75-cm2 culture
flasks in DMEM supplements with 10% FBS and 1% penicillin-streptomycin. Cells
(1 x 105) were placed on cover slips in 6-well plates and cultured at 37 °C for 24 h.
The mediums were removed from 6-well plates. The cells were then washed with
PBS and serum-free media. FITC-labeled peptides were used to treat cells in the
serum-free media for 20 min. Then, the medium was removed, and the cells were
washed with PBS twice in order to remove the unbound peptides. Alexa Fluor 594
wheat agglutinin (2.5 µg/mL in PBS) was then used to treat cells for 10 min to stain
the cell membranes. The cells were washed two times with PBS and fixed with 4%
paraformaldehyde for 15 min. The cover slips were attached to the slides with a drop
of SlowFade antifade reagent. The cells were then imaged under brand BZ-X710
All-in-One Fluorescence Microscope (Keyence, Itasca, USA) using green and red
filters with 40 X objective. The samples prepared for fluorescence microscope were
also used for visualization by an inverted Leica DMIRE2 confocal microscope (Leica
Microsystems GmbH, Germany) with Yokogawa CSUX1 63X magnification
(Yokogawa Electric Corporation, Japan) to verify internalization. All the images were
analyzed and transformed to the bmp format by Image J software.
3.4. Result and Discussion
Ligand binding assays (LBA) is an analytical assay used to measure the strength
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of ligand binding to receptors. Numerous techniques are used to measure the ligand
binding including fluorescence resonance energy transfer (FRET), fluorescence
polarization (FP), and surface plasmon resonance (SPR). In this study, the specificity
of HER2-targeting peptides has been confirmed. HER2 specific - peptides should
preferentially bind to tumor cancer cells that over express HER2 rather than to normal
cells. Binding specificity studies are used to determine the specific binding and uptake
of different molecules in the target cells. Confocal and fluorescent images provide the
visual information about the peptides binding to target cells. To determine the
influence of cysteine added in peptide sequence, four specific peptides ER1
(MARAKE), ER1C (MARAKEC), ER2 (MARSGL), ER2C (MARSGLC), and one
random peptide RA (MAKRAE) were chosen to study the binding specificity.
Three different cell lines were used to study the binding specificity of peptides.
MDA-MB-361 cells and ZR-75-1 cells are cell lines that overexpress HER2, while
HEK293 cells are the human normal kidney cells that do not express HER2 [84]. All
four FITC-labeled peptides and cysteine-modified peptides were found to be
specifically bound to the cell membrane and internalized into the cells that
overexpressed HER2 within the first 20 min at 37˚C. As shown in Figure 3.1- Figure
3.4, significant higher fluorescence was observed in MDA-MB 361 and ZR 75-1 cells
as compared with the negligible fluorescence found in HEK 293 cells, which
demonstrated the binding specificity of the four specific peptides towards HER2. In
the case of FITC-labeled control peptide RA1, no binding was observed in all of three
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cell lines. The binding specificity of the ER1 and ER2 peptides confirmed the claim in
the literature [83], and the binding specificities of cysteine-modified peptides were
also proved. The result of the confocal microscopy studies suggested that
cysteine-modified peptides retain their binding capability to HER2-positive cell lines.
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Figure 3.1 Confocal images of peptide ER1. Alexa Fluor594 column represents
the cell treated with membrane dye, FITC-PEP-MARAKE displays the cells treated
with FITC conjugated peptide and overlap column represent the merge of the two
images.
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Figure 3.2 Confocal images of peptide ER1C. Alexa Fluor594 column represents
the cell treated with membrane dye, FITC-PEP-MARAKEC displays the cells treated
with FITC conjugated peptide and overlap column represent the merge of the two
images.
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Figure 3.3 Confocal images of peptide ER2. Alexa Fluor594 column represents
the cell treated with membrane dye, FITC-PEP-MARSGL displays the cells treated
with FITC conjugated peptide and overlap column represent the merge of the two
images.
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Figure 3.4 Confocal images of peptide ER2C. Alexa Fluor column represents the
cell treated with membrane dye, FITC-PEP-MARSGLC displays the cells treated with
FITC conjugated peptide and overlap column represent the merge of the two images.
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Figure 3.5 Confocal images of peptide RA. Alexa Fluor594 column represents
the cell treated with membrane dye, FITC-PEP-MAKRAE displays the cells treated
with FITC conjugated peptide and overlap column represent the merge of the two
images.
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CHAPTER 4:

SYNTHESIS AND CHARACTERIZATION OF

PEPTIDE-DRUG CONJUGATES AND HYBRID PEPTIDES

4.1. Introduction
As stated in Chapter 1, peptide–drug conjugates share similar concepts with
antibody–drug conjugates; the flexibility of PDCs in structure and low molecular
weight lead to enhanced drug loading and higher penetration into the solid tumor
tissues. The peptides used in PDCs can be divided into two categories: cell
penetration peptides (CPPs) and cell-targeting peptides (CTPs). The linker used in
PDCs can be categorized into two types: non-cleavable linkers and cleavable linkers.
Carbon chain, amide bond, and ether bond are commonly used in non-cleavable linker
designs. They are stable in biological fluids and can reduce the premature drug release
in the blood circulation. PDCs with the cleavable linkers can release the drug after
reaching the tumor site. The cleavable linkers can be further divided into three
different types: pH-sensitive, redox-sensitive, and enzyme-sensitive. Hydrazone bond,
vinyl ether bond, and acetal bond are pH-sensitive linkers that release drug in an
acidic environment in the endosomes. Redox-sensitive linkers release the drugs in
endosomes mediated by GSH. The cleavage of the enzyme-sensitive linkers are
mediated released drug by Cathepsin B. For the objective of this study,
HER2-targeting peptides MARAKE and MARSGL were chosen as targeting moiety
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to design the peptide–drug conjugates. Two type linkers: non-cleavable
Maleimidocaproyl (MC) linker and cleavable valine-citrulline (VC) linker were used
to link the cytotoxic drug MMAE and targeting peptides to form the peptide–drug
conjugates.
Cytolytic peptides, which emerge from eukaryotic cells, were found to have
anticancer function. In this study, a design based on the fusion of cytolytic peptide as
anticancer agent and HER2 binding peptide was carried out to generate a
“peptide-peptide conjugate” for targeted cancer delivery of cytolytic peptide [84]. In
our study, a lytic peptide, melittin [67] that was developed from nanobees was chosen
to fuse with HER2-targeting peptide in order to form hybrid peptides. Table 4.1
indicates the design of hybrid lytic peptides. When cytolytic peptides are used in the
design, non-cleavable amid linkage is used.
The purpose of this chapter is to synthesize, characterize and purify peptide-drug
conjugates and hybrid peptides for in vitro studies.
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Figure 4.1 Structure of MMAE（1）

Figure 4.2 Mechanism of peptide–drug conjugates reaction
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Figure 4.3 Structure of PDC based on MC-MMAE (2). The linker consisting of
attachment group maleimidocaproyl is marked by red. The drug MMAE is blue while
the peptide is green.

Figure 4.4 Structure of PDC based on VC-MMAE (3). The linker consisting of
cleavable dipeptide valine (Val)-citrulline(Cit), the spacer (p-aminobenzylcarbamate)
and the attachment group maleimidocaproyl. The dipeptide is marked by yellow; the
spacer is pink; the attachment group is red; the color of drug MMAE and the peptide
are the same as Figure 4.3.
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Table 4.1 Summary designing of peptide-drug conjugates
Name of PDCs
YW1 (4)
YW2 (5)
YW3 (6)
YW4 (7)

Peptide
MARAKEC
MARSGLC
MARAKEC
MARSGLC

Linker
MC-MMAE (2)
MC-MMAE (2)
VC-MMAE (3)
VC-MMAE (3)

Table 4.2 Sequence of lytic peptide and hybrid peptides
Peptides
LY1 (8)
HY1 (9)
HY2 (10)

Structure
GIGAVLKVLTTGLPALISWIKRKRQQ
MARAKE-GGG-GIGAVLKVLTTGLPALISWIK
RKRQQ
MARSGL-GGG-GIGAVLKVLTTGLPALISWIKR
KRQQ

MW
2847.46
3705.44
3634.36
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Figure 4.5 Model of Antibody-drug conjugate (a), peptide-drug conjugate (b),
and hybrid peptide (c).
4.2. Materials
MC-MMAE and VC-MMAE were obtained from Boc Science (Shirley, NY,
USA). MMAE was ordered from Medchem Express (New Jersey, USA), and
N,N’-dimethylformamide (DMF) and Triethylamine (TEA) were purchased from
Axros Organics (New Jersey, USA).
4.3. Methods
4.3.1.

Synthesis of MC-MMAE Peptide–drug Conjugate

Peptide (1.1 eq) with a free thiol group and MC-MMAE (1 eq) were dissolved
separately in DMF. The peptide was added to the MC-MMAE DMF solution
drop-wise, to which 10 µL of TEA was added into the reaction mixture under
nitrogen protection. The reaction mixture was stirred for 2.5 h at the room
temperature and then evaporated under reduced pressure.
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4.3.2.

Synthesis of VC-MMAE Peptide–drug Conjugate

VC-MMAE was used in the place of MC-MMAE and other procedures and
conditions were the same as that described in 4.3.1.
4.3.3.

Purification of Peptide–drug Conjugate

All peptide–drug conjugates were dissolved in methanol and then purified on
RP-HPLC with the Agilent 1100 System (Agilent Zorbax SB-C18; 4.6 x 150 mm,
3.5-µm column) at 230 and 280 nm. The mobile phase solvents were water (solvent A)
and methanol (solvent B), and both solvents were used with 0.1% TFA.

Elution was

performed with a linear gradient for 30 min from 5% to 95% solvent B at the flow
rate of 1 mL/min at 23.8°C.
4.3.4.

Characterization of Peptide–drug Conjugate

The products were characterized by using Electro Spray Ionization Mass
Spectrometry (ESI-MS; AB Sciex PI 3000 Ion Trap Mass Spectrometer). The samples
were prepared in methanol and water mixtures and infused at the speed of 10 µL/min.
Ion source parameters are listed as follows: Nebulizer Gas (NEB) 8 Psi, Ion Spray
Voltage 5500 V; TEM （Temperature） 300℃; CUR （Curtain Gas） 8 Psi.
4.4. Results and Discussion
In this study, HER2-targeting peptide ER1 and ER2 were selected to synthesize
peptide-drug conjugates. Cysteine was used to modify HER2-targeting peptides to
generate a functional group for the linkage to the drug. The specificity of
cysteine-modified peptide ER1C and ER2C were retained after modification as
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confirmed in Chapter 3.
These modified targeting peptides were conjugated with MMAE, which is a
non-selective but potent tubulin polymerization inhibitor that develops high toxicity
in tumor cells. Two type linkers: non-cleavable Maleimidocaproyl (MC) linker and
cleavable valine-citrulline (VC) linker were used to prepare the peptide–MMAE
conjugates. Both MC linker and VC linker have the maleimide group, which can react
with the thiol group and form the thiol-ether bond between the peptide and the drug.
The reaction mechanism of thiol group and maleimide group was illustrated in Figure
4.2.
All the intermediate and final products were characterized by ESI-MS as shown
in Table 4.2. The mass spectra for MMAE, MC-MMAE, VC-MMAE, YW1, YW2,
YW3, and YW4 were observed as both single- and double-charge species (Figures
4.9–4.15). RP-HPLC was performed to check the purity and to purify the PDCs. The
purity of all compounds was found to be >95% (Figure 4.5-4.8; Table 4.2). All PDCs
were purified through RP-HPLC on the C18 column and used for further experiments.
The lytic peptide and hybrid peptides were successfully synthesized and were
characterized by ESI-MS as shown in Table 4.3. The mass spectra for LY1, HY1,
HY2 were observed from quadruple to octuple charge (Figure 4.16-4.18).
In this chapter, four peptide-drug conjugates were successfully synthesized and
purified. ESI mass spectrum was used to characterize the molecular weight of
conjugates, while HPLC was used to purify the conjugates. The purities of
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peptide-drug conjugates were confirmed more than 95%.

Peptide with more than 90%

purity also named high-level of purity peptide, which is beneficial for in-vitro
cytotoxicity studies.
The lytic and hybrid peptides were also successfully synthesized and
characterized. However, the purities of lytic and hybrid peptides were range from 69%
to 73%, which was considered in mid-range levels of purity. This level of purity is
appropriate for screenings peptides in the preliminary studies. Lytic and hybrid
peptides cytotoxicity studies were performed in Chapter 5.

Table 4.2 MMAE, intermediates and PDC MS and HPLC data
Molecule
MMAE (1)
MC-MMAE (2)
VC-MMAE (3)
YW1 (4)
YW2 (5)
YW3 (6)
YW4 (7)

HPLC Purity (%)
99%
99%
99%
98%
98%
99%
98%

MW (g/mol)
718
911.2
1316.65
1720
1649
2124
2053
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Figure 4.5 HPLC chromatogram of YW1

Figure 4.6 HPLC chromatogram of YW2

Figure 4.7 HPLC chromatogram of YW3

93

Figure 4.8 HPLC chromatogram of YW4
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Figure 4.10 ESI Mass Spectrum of MC-MMAE
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Figure 4.14 ESI Mass Spectrum of YW3
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Figure 4.15 ESI Mass Spectrum of YW4
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Table 4.3 Lytic peptide and hybrid peptides MS and HPLC data
Peptides
LY1 (8)
HY1 (9)
HY2 (10)

Purity
73%
69%
70%

MW
2847.46
3705.44
3634.36
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CHAPTER 5:

IN VITRO CYTOTOXICITY OF PEPTIDE-DRUG
CONJUGATES AND HYBRID PEPTIDES

5.1. Introduction
Cell viability and cytotoxicity study have been used for drug biological evaluation,
screening, and cytotoxicity on the cells in vitro to observe the response on cell growth,
reproduction, and morphology. Cell cytotoxicity test is an important indicator for
toxicity evaluation of compound as it is simple, fast, and highly sensitive. Various
cytotoxicity assays are based on the cell viability at different stages of the cell cycles.
Lactate dehydrogenase (LDH) assay and trypan blue exclusion assay are membrane
integrity assay used to evaluate the extent of cell damage by cytotoxicity agents. To
analyze the cellular metabolic activity, MTT [3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide] assay is a sensitive and reliable indicator as
compared to ATP and 3H-thymidine incorporation assay, which is used to measure
the end-point of viable cells. Despite the fact that MTT assay is a sensitive and
reliable method, drug-efflux pump inhibitor or anti-oxidants may interfere with the
MTT assay resulting in a false test result.
To overcome the drawback of MTT assay, Sulforhodamine B (SRB) assay was
proposed by Skehan in 1990 and applied to large-scale drug screening by Vichal and
Kirtikara in 2006 [86][87]. SRB assay determines cell viability by measuring the
cellular protein content. The death of cells can be observed by staining the cellular
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DNA with propidium iodide staining method, followed by flow cytometry [88]. SRB
is a protein dye that binds to protein in a pH-dependent condition of cell protein
amino acid residues fixed by trichloroacetic acid. SRB binds to protein in mild acidic
condition, while it can be extracted and solubilized for quantitative measurement
under basic conditions [86]. Linear relation between the cell number and cellular
protein measured at cellular densities can reach 1–200‰ of confluence. As compared
to MTT and other cell cytotoxicity assay, the SRB assay was performed with similar
results and a stable end-point makes it an appropriate and sensitive assay for
measuring the cytotoxicity of peptide–drug conjugates.
The purpose of this chapter is to utilize SRB assay to measure the cytotoxicity of
synthesized peptide-drug conjugates and hybrid peptides.
5.2. Materials
MDA-MB 361, ZR75, and HEK293 cells were purchased from ATCC (Manassas,
VA, USA). Dulbecco’s modified eagle medium (DMEM), 4.5 g/L glucose,
L-glutamine and 1% penicillin-streptomycin (5000 I.U./mL) were obtained from
Mediatech (Manassas, VA, USA). Sodium pyruvate containing 10% heat-inactivated
fetal bovine serum was ordered from Gemini (Sacramento, CA, USA).
Trichloroacetic acid, acetic acid, and tris base were obtained from Chem-Impex
International Inc. (Wood Dale, IL, USA). SRB was obtained from MP Biomedical,
Inc. (Santa Ana, CA, USA). The 96-well plates were purchased from Santa Cruz
Biotechnology, Inc..
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5.3. Methods
The cytotoxicity study of MMAE, peptide–drug conjugates, lytic peptides, and
hybrid peptides was performed using MDA-MB 361, ZR75 cells, and HEK293 cells.
The cells were cultured in 75-cm2 culture flasks in DMEM medium supplements with
10% FBS and 1% penicillin-streptomycin. The cells were seeded into 96-well plates
at a density of 1.25 x 104/mL and grown for 24 h until they were attached to the wells.
The cells were then incubated with MMAE, peptides, and peptide–drug conjugates at
the following concentrations: 0.0001, 0.001, 0.01, 0.1, 1, 10, 100, 1000, and 10000
nM. After 72 hours, the 96-well plates were removed from incubator and 50-µL of
pre-chilled 50% trichloroacetic acid was added to each well and then the plates were
stored at 4°C refrigerator for 1 hour to fix the cells. Finally, the cells were washed
with deionized water 5 times. After drying at the room temperature, the cellular
proteins were stained by adding 60 µL of 0.4% SRB prepared in 1% acetic acid. After
20-min staining, the unbound dye was removed by washing with 1% acetic acid for 5
times. After drying in the air overnight, the cell-bounded SRB was dissolved in 150
µL of 10 mM non-buffered Tris-base solution at pH 10.5. The SRB absorbance was
measured at 490 nm wavelength by using a microplate reader (BioTek Instruments,
Inc., VT, USA).
The percent of cell viability was calculated by using the following equation:
Percent of cell cytotoxicity = (At-Ab)/Ab
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At = Absorbance value of test compound
Ab = Absorbance value of blank
Percent of cell viability = 1-(Percent of cell cytotoxicity)
The percent of cell viability was analyzed using the Graph Pad Prism Version 7
software (GraphPad Software Inc, CA, USA) with a nonlinear regression
dose-response curve fit (variable slope three parameter equation).
5.4. Results and Discussion
Cytotoxicity studies were performed to determine the potency of peptide, drug,
and peptide–drug conjugates. As shown in Table 5.1, the tubulin inhibitor MMAE
demonstrated similar potent cytotoxicity and IC50 in both HER2-positive cell line and
HER2-negative normal cell line, which indicated the lack of specificity of the drug.
Peptides showed low toxicity in both HER2-positive cell lines and normal cell line as
compared with MMAE.
As for the toxicity of MMAE intermediate, the MC-MMAE exhibited a low
toxicity similar to that of the peptides. Furthermore, when conjugating MC-MMAE
with HER2-targeting peptide, the peptide–drug conjugates YW1 and YW2 presented
an even lower potency than MMAE intermediate in both HER2-positive cell lines and
normal cell line. There is the minor difference of toxicity of MC-MMAE PDC
between the HER2-positive cell line and HER2-negative cell line as shown in Table
5.1. This result indicated that PDCs with MC linker selectively bind to HER2
overexpressed cell lines due to the lower toxicity in the normal cell line. MC-MMAE
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PDCs demonstrated lower toxicity in HER2-negative cell line as compared to the
toxicity in the HER2-positive cell line. This may be attributed to the non-cleavable
linker maleimidocaproyl, when conjugated with MMAE, the structure of MMAE was
modified and the toxicity of MMAE was altered. Moreover, the amide bond between
6-maleimidocaproic acid and MMAE is stable and difficult to be cleaved by a
protease enzyme.
In case of a cleavable MMAE intermediate, the MC-VC-MMAE exhibited
similar high potency as MMAE, when MC-VC-MMAE was conjugated with
HER2-targeting peptide, the peptide–drug conjugates YW3 and YW4 presented with
higher potency in the HER2-positive cell lines MDA-MB 361 and ZR75 and a distinct
lower toxicity in the normal cell line HEK 293 in comparison to MMAE. Both
peptide-drug conjugates displayed higher toxicity in HER2-positive cell lines
MDA-MB 361 and ZR 75 as compared to the normal cell line HEK293 as shown in
Table 5.1. This result indicated that the peptide–drug conjugates based on cleavable
linker selectively binds to and internalizes via the receptor-mediated endocytosis in
HER2 overexpressed cell lines.
The proposed cell-killing mechanism of PDCs based on the MC-VC-PABC
linker may start upon binding of targeting peptides to HER2, which is overexpressed
on the surface of the cancer cells. After binding, the PDC-HER2 complex undergoes
internalization through receptor-mediated endocytosis. Following the internalization,
the complex releases cytotoxic agents after protease (Cathepsin B) cleavage. Then,
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after spontaneous elimination of p-aminobenzoyloxycarbonyl (PABC), the cytotoxic
agent MMAE was released and it exerted its cytotoxic effect by binding to tubulin
and inhibiting polymerization, leading to apoptosis of the target cells. In comparing to
the MC-MMAE PDC results, it can conclude that the linker or derivation of MMAE
to link to targeting peptides play a crucial role in cytotoxicity for HER2 overexpress
cells. Although the data from MC MMAE PDC would not provide indication of
specificity of binding and internalization, the MC MMAE PDC could bind and
internalized into HER 2 overexpress cells.

However, the low potency of MC

MMAE may not exert its cytotoxicity. The significant low toxicity of both
MC-MMAE PDCs and VC-MMAE PDCs in HER2 overexpress cells compared to
normal cells indicated the specificity of PDCs.
As shown in Table 5.2, the lytic peptide demonstrated similar cytotoxicity and
IC50 in both HER2-positive cell line and normal cell line, which indicated the lack of
specificity of the lytic peptides. 10-folds higher toxicity of hybrid peptides than lytic
peptides was observed on HER2-positive cell line ZR 75 and MDA-MB 361.
Approximately 5-folds lower toxicity of hybrid peptide than lytic peptides was
detected on the normal cell line. Furthermore, the significant higher cytotoxicity of
hybrid peptides on HER2 positive cell line compared to the cytotoxicity on the normal
cell line exhibited the enhanced specificity of hybrid peptides. By conjugating the
lytic peptide with HER2-targeting peptide, the hybrid peptides demonstrated
selectivity on killing HER2 positive cell lines.
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Table 5.1 In-vitro cytotoxicity of PDCs and free MMAE, MMAE intermediate on
HER2 positive cell lines and normal cell lines**

Cell line

	
  

MMAE*
MC-MMAE
YW1
YW2
VCMMAE
YW3
YW4
MARAKE

ZR75

MDAMB 361

HEK293

IC50 (nM, Avg±SD)
7.59±0.39
(1.33±0.09)×104
(3.95±0.07)×104
(7.40±0.91)×104
4.43±0.13
(7.00±0.32)×10-3
(1.30±0.02)×10-2
(5.52±0.08)×104

(1.35±0.02)×10-1
(7.07±0.14)×103
(1.46±0.02)×104
(3.89±0.04)×104
(4.16±0.12)×10-1
(3.90±0.16)×10-2
(1.50±0.05)×10-2
(1.80±0.06)×104

6.68±0.15
(1.04±0.13)×103
(3.29±0.07)×104
(3.91±0.04)×104
5.45±0.37
(1.22±0.17)×102
(1.55±0.28)×102
(6.11±0.17)×104

Abbreviations: Avg=Average (n=6); SD= Standard deviation
* P<0.001 P-values were determined by analysis of variance (ANOVA).
** P<0.0001 P-values were determined by analysis of variance (ANOVA).
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Table 5.2 In-vitro cytotoxicity of lytic peptide and hybrid peptides on
HER2-positive cell lines and normal cell lines*

Cell line

LY1
HY1
HY2
MARAKE

ZR75

83±1.5
6.58±0.61
2.88±0.27
(5.52±0.03)×104

MDAMB361

HEK293

IC50 (nM, Avg±SD)
301±12
(1.30±0.01)×102
21.1±1.4
(5.01±0.09)×102
32.3±0.27
(5.45±0.13)×103
(1.80±0.12)×104

(6.11±0.27)×104

Abbreviations: Avg=Average (n=6); SD= Standard deviation
* P<0.001 P-values were determined by analysis of variance (ANOVA).
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Figure 5.1 IC50 value of MMAE, MC-MMAE, peptide and PDC on MDA-MB
361 cell line.

Figure 5.2 IC50 value of MMAE, MC-MMAE, peptide and PDC on ZR75 cell
line.
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Figure 5.3 IC50 value of MMAE, MC-MMAE, peptide and PDC on HEK293 cell
line.

Figure 5.4 IC50 value of MMAE, VC-MMAE, peptide and PDC on MDA-MB 361
cell line.
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Figure 5.5 IC50 value of MMAE, VC-MMAE, peptide and PDC on ZR75 cell
line.

Figure 5.6 IC50 value of MMAE, VC-MMAE, peptide and PDC on HEK293 cell
line.
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Figure 5.7 IC50 value of lytic peptide and hybrid peptides on MDA-MB 361 cell
line.

Figure 5.8 IC50 value of lytic peptide and hybrid peptides on ZR75 cell line.
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Figure 5.9 IC50 value of lytic peptide and hybrid peptides on HEK293 cell line
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CHAPTER 6:

SUMMARY AND CONCLUSIONS

In this study, HER2-targeting peptides MARAKE and MARSGL were used as a
target moiety to design peptide–drug conjugates and hybrid peptides. Both
non-cleavable and cleavable linkers were used for developing the peptide–drug
conjugates.

Melittin, a cytolytic peptide was used as a cytotoxic agent to conjugate

with same HER-targeting peptides to form the hybrid peptides.
To verify the binding specificity of targeting peptides and their derivative, two
cell lines that overexpress HER2 and one control cell line without HER2 expression
were used to prove the specificity of the HER2-targeting peptides. Confocal
microscopy study was performed to verify the uptake of peptides on these cell lines.
The result indicated that the peptides and cysteine-modified peptides were bond and
internalized selectively into the HER2-overexpressed cell lines. The random peptide
as control showed negligible uptake as compared to HER2-targeting peptides.
Two designs using peptide-drug conjugate were studied in this thesis. Both
designs used HER2 binding peptides as targeting moieties, but the drug portion of
peptide-drug conjugate was either cytolytic peptide or cytotoxic small molecule.
Peptide–drug conjugates were designed by linking HER2-targeting peptides
and MMAE, a highly potent and non-specific anti-cancer drug, via MC or VC linker.
The results showed that the MC linker-based peptide–drug conjugates did not exhibit

117

any toxicity in both HER2-overpressed cell lines and normal cell lines. To the
cleavable VC linker, the peptide–drug conjugates were 10-folds more cytotoxic to
HER2-overpressed cancer cells as compared to the drug itself and were 100-fold less
cytotoxic to cells with no HER2 expression. These results suggest that the use of
peptide–drug conjugate approach could be a potential approach in cancer therapy.
Hybrid peptides with cytolytic peptide and HER2-targeting peptide MARAKE
and MARSGL were also designed by using a GGG as a spacer to link the two
peptides. The sequence of the designed hybrid peptides was 35 amino acids.

Due to

the high molecular weight, high purity of hybrid peptides was not obtained. The
purity of peptides was 70 %. However, the purity of peptide was sufficient for in vitro
toxicity study. The preliminary cytotoxicity study demonstrated limited potential of
hybrid peptides. Both hybrid peptides showed slightly enhanced toxicity in the
HER2-overpressed cell lines as compared to the lytic peptide while reducing toxicity
to non-HER2 overexpress cells. These results may lead to the further studies in
designing hybrid peptides with shorter and more potent lytic peptides.
In

conclusion,

HER2-targeted

delivery

peptide–drug

conjugates

were

successfully synthesized by using an enzyme-sensitive cleavable linker. Peptide–drug
conjugates using non-cleavable linker did not enhance the toxicity to the cancer cell
lines. Hybrid peptide is a potential approach for cancer therapy but further research
with different lytic peptides will be needed.
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